ALDACTONE® Highlights

(spironolactone)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ALDACTONE safely and effectively. See full prescribing information for ALDACTONE.

ALDACTONE (spironolactone) tablets for oral use
Initial U.S. Approval: 1960

INDICATIONS AND USAGE

ALDACTONE is an aldosterone antagonist indicated for:

•
The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1).
•
Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2).
•
The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3).
•
Treatment of primary hyperaldosternism for: (1.4)
o
Short-term preoperative treatment
o
Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia

DOSAGE AND ADMINISTRATION

•
Heart Failure: Initiate treatment at 25 mg once daily (2.2).
•
Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses (2.3).
•
Edema: Initiate therapy in a hospital setting and titrate slowly. The recommended initial daily dose is 100 mg in single or divided doses (2.4).
•
Primary hyperaldosteronism: Initiate treatment at 100 to 400 mg in preparation for surgery. In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient (2.5).

DOSAGE FORMS AND STRENGTHS

Tablets: 25 mg, 50 mg, and 100 mg (3)

CONTRAINDICATIONS

ALDACTONE is contraindicated in patients with (4):

▪
Hyperkalemia
▪
Addison's disease
▪
Concomitant use of eplerenone

WARNINGS AND PRECAUTIONS

•
Hyperkalemia: Monitor serum potassium within one week of initiation and regularly thereafter (5.1).
•
Hypotension and Worsening Renal Function: Monitor volume status and renal function periodically (5.2).
•
Electrolyte and Metabolic Abnormalities: Monitor serum electrolytes, uric acid and blood glucose periodically (5.3).
•
Gynecomastia: ALDACTONE can cause gynecomastia (5.4).

ADVERSE REACTIONS

The most common adverse reaction with ALDACTONE treatment is gynecomastia (5.4, 6).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

DRUG INTERACTIONS

•
Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1).
•
Lithium: Increased risk of lithium toxicity (7.2).
•
NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of ALDACTONE (7.3).
•
Digoxin: ALDACTONE can interfere with radioimmunologic assays of digoxin exposure (7.4).
•
Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5).
•
Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of ALDACTONE (7.6).
•
Abiraterone: May increase prostate-specific antigen (PSA) levels (7.7).

USE IN SPECIFIC POPULATIONS

▪
Pregnancy: Based on animal data, ALDACTONE may affect sex differentiation of the male during embryogenesis (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2023

Find ALDACTONE® medical information:

Find ALDACTONE® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ALDACTONE® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ALDACTONE safely and effectively. See full prescribing information for ALDACTONE.

ALDACTONE (spironolactone) tablets for oral use
Initial U.S. Approval: 1960

INDICATIONS AND USAGE

ALDACTONE is an aldosterone antagonist indicated for:

•
The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1).
•
Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2).
•
The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3).
•
Treatment of primary hyperaldosternism for: (1.4)
o
Short-term preoperative treatment
o
Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia

DOSAGE AND ADMINISTRATION

•
Heart Failure: Initiate treatment at 25 mg once daily (2.2).
•
Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses (2.3).
•
Edema: Initiate therapy in a hospital setting and titrate slowly. The recommended initial daily dose is 100 mg in single or divided doses (2.4).
•
Primary hyperaldosteronism: Initiate treatment at 100 to 400 mg in preparation for surgery. In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient (2.5).

DOSAGE FORMS AND STRENGTHS

Tablets: 25 mg, 50 mg, and 100 mg (3)

CONTRAINDICATIONS

ALDACTONE is contraindicated in patients with (4):

▪
Hyperkalemia
▪
Addison's disease
▪
Concomitant use of eplerenone

WARNINGS AND PRECAUTIONS

•
Hyperkalemia: Monitor serum potassium within one week of initiation and regularly thereafter (5.1).
•
Hypotension and Worsening Renal Function: Monitor volume status and renal function periodically (5.2).
•
Electrolyte and Metabolic Abnormalities: Monitor serum electrolytes, uric acid and blood glucose periodically (5.3).
•
Gynecomastia: ALDACTONE can cause gynecomastia (5.4).

ADVERSE REACTIONS

The most common adverse reaction with ALDACTONE treatment is gynecomastia (5.4, 6).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

DRUG INTERACTIONS

•
Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1).
•
Lithium: Increased risk of lithium toxicity (7.2).
•
NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of ALDACTONE (7.3).
•
Digoxin: ALDACTONE can interfere with radioimmunologic assays of digoxin exposure (7.4).
•
Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5).
•
Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of ALDACTONE (7.6).
•
Abiraterone: May increase prostate-specific antigen (PSA) levels (7.7).

USE IN SPECIFIC POPULATIONS

▪
Pregnancy: Based on animal data, ALDACTONE may affect sex differentiation of the male during embryogenesis (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2023
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.